Switch theme
Sign up to access all valuation multiples
Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel.
n/a
Last FY Revenue $0.5M
Last FY EBITDA -$0.7M
$4.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Genxone achieved revenue of $0.5M and an EBITDA of -$0.7M.
Genxone expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Genxone valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.5M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.2M | XXX | XXX | XXX |
| Gross Margin | XXX | 36% | XXX | XXX | XXX |
| EBITDA | XXX | -$0.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -144% | XXX | XXX | XXX |
| EBIT | XXX | -$1.0M | XXX | XXX | XXX |
| EBIT Margin | XXX | -206% | XXX | XXX | XXX |
| Net Profit | XXX | -$1.0M | XXX | XXX | XXX |
| Net Margin | XXX | -220% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Genxone's stock price is PLN 6 (or $2).
Genxone has current market cap of PLN 19.8M (or $5.3M), and EV of PLN 15.0M (or $4.0M).
See Genxone trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.0M | $5.3M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Genxone has market cap of $5.3M and EV of $4.0M.
Genxone's trades at 8.4x EV/Revenue multiple, and -5.8x EV/EBITDA.
Equity research analysts estimate Genxone's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genxone's P/E ratio is not available.
See valuation multiples for Genxone and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.3M | XXX | $5.3M | XXX | XXX | XXX |
| EV (current) | $4.0M | XXX | $4.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 8.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -5.8x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -4.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -5.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -6.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGenxone's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Genxone's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Genxone's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Genxone and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -144% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 242% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genxone acquired XXX companies to date.
Last acquisition by Genxone was XXXXXXXX, XXXXX XXXXX XXXXXX . Genxone acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is Genxone headquartered? | Genxone is headquartered in Poland. |
| Is Genxone publicy listed? | Yes, Genxone is a public company listed on WAR. |
| What is the stock symbol of Genxone? | Genxone trades under GX1 ticker. |
| When did Genxone go public? | Genxone went public in 2020. |
| Who are competitors of Genxone? | Similar companies to Genxone include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Genxone? | Genxone's current market cap is $5.3M |
| Is Genxone profitable? | Yes, Genxone is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
